Ionis Pharmaceuticals

Youtube Subscribe

Open: 39.76 Close: 39.33 Change: -0.43

The top 11 things about Ionis Pharmaceuticals Company Inc found by an AI.

Are looking for the most relevant information about Ionis Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Ionis Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Ionis, Pharmaceuticals, Free, last, rating, NASDAQIONS, Get, and the most common words in the summary are: therapeutic, pharmaceutical, excipient, phase, pharma, ionis, sodium, . One of the sentences in the summary was: Ionis is conducting phase 3 trials for Donidalorsen, an antisense medicine …

Concept Map

Semantic Network

Stock Summary

SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin am.

Today's Summary

Citigroup upgraded Ionis Pharmaceuticals from a “sell” rating to a ‘neutral’ rating. Ionis is conducting phase 3 trials for Donidalorsen, an antisense medicine forhereditary angioedema.

Today's News

Ionis Pharmaceuticals ( NASDAQ:IONS – Get Free Report ) last issued its quarterly earnings data on Wednesday, May 3rd. Citigroup upgraded Ionis. Pharmaceuticals from a “sell” rating to a ‘neutral’ rating. Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has seen its stock decline by about 11% over the last week, trading at levels of around $55. Ionis Pharmaceuticals is conducting phase 3 trials for Donidalorsen, an antisense medicine forhereditary angioedema (a condition that affects blood vessels and can lead torapid swelling of limbs, face, trachea etc) Access the Immunology Newsmakers Dashboard (Free Excel) Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (clinicaltrials.gov) - P3.

Stock Profile

"Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California."

Keywords

The game is changing. There is a new strategy to evaluate Ionis Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Ionis, Pharmaceuticals, Free, last, rating, NASDAQIONS, Get, and the most common words in the summary are: therapeutic, pharmaceutical, excipient, phase, pharma, ionis, sodium, . One of the sentences in the summary was: Ionis is conducting phase 3 trials for Donidalorsen, an antisense medicine forhereditary angioedema.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #pharmaceutical #excipient #phase #pharma #ionis #sodium.

Read more →

Youtube Subscribe

---